Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors. 2017

P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.

In our endeavour towards the development of potent cytotoxic agents, a series of some new curcumin inspired indole analogues, in which indole and phenyl moieties are linked on either sides of 1,5-diaryl-1,4-pentadien-3-one system have been synthesized and characterized by spectral data. All the newly synthesized analogues were tested for their cytotoxic potential against a panel of eight cancer cell lines namely, lung (A549), breast (MDA-MB-231, BT549 and 4T1), prostate (PC-3, DU145), gastric (HGC-27) and cervical (HeLa). Notably, among all the compounds tested, compounds 11c, 11d and 11f showed potent growth inhibition on PC-3 and BT549 with IC50 values in the range of 3.12-6.34 μM and 4.69-8.72 μM respectively. The most active compound (11c) was also tested on RWPE-1 (normal prostate) cells and was found to be safe compared to the PC-3 cells. In tubulin polymerization assay, compounds 11c and 11f effectively inhibited microtubule assembly with IC50 values of 10.21 ± 0.10 and 8.83 ± 0.06 μM respectively. The results from molecular modelling studies revealed that these compounds bind at the colchicine binding site of the tubulin. Moreover, DAPI and acridine orange/ethidium bromide staining studies indicated that compounds 11c and 11f can induce apoptosis in PC-3 cells. Further flow-cytometry analysis revealed that compound 11c arrests PC-3 cells in G2/M phase of the cell cycle while compound 11f treatment resulted in moderate increase in the G2/M population. Additionally, the treatment by these compounds led to the impairment of mitochondrial membrane potential (DΨm) in PC-3 cells.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D003474 Curcumin A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-,Curcumin Phytosome,Diferuloylmethane,Mervia,Turmeric Yellow,Phytosome, Curcumin,Yellow, Turmeric
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050257 Tubulin Modulators Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. Microtubule Modulator,Tubulin Inhibitor,Tubulin Modulator,Tubulin Polymerization Inhibitor,Tubulin Polymerization Promoter,Tubulin Promoter,Microtubule Modulators,Tubulin Inhibitors,Tubulin Polymerization Inhibitors,Tubulin Polymerization Promoters,Tubulin Promoters,Inhibitor, Tubulin,Inhibitor, Tubulin Polymerization,Inhibitors, Tubulin,Inhibitors, Tubulin Polymerization,Modulator, Microtubule,Modulator, Tubulin,Modulators, Microtubule,Modulators, Tubulin,Polymerization Inhibitor, Tubulin,Polymerization Inhibitors, Tubulin,Polymerization Promoter, Tubulin,Polymerization Promoters, Tubulin,Promoter, Tubulin,Promoter, Tubulin Polymerization,Promoters, Tubulin,Promoters, Tubulin Polymerization

Related Publications

P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
January 2024, European journal of medicinal chemistry,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
October 2016, European journal of medicinal chemistry,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
March 2013, Organic and medicinal chemistry letters,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
June 2019, Computational biology and chemistry,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
July 2016, ChemMedChem,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
June 2019, Journal of medicinal chemistry,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
January 2020, Bioorganic & medicinal chemistry letters,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
April 2022, Drug development research,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
August 2020, Bioorganic & medicinal chemistry letters,
P V Sri Ramya, and Srinivas Angapelly, and Lalita Guntuku, and Chander Singh Digwal, and Bathini Nagendra Babu, and V G M Naidu, and Ahmed Kamal
October 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!